1nhaler Ltd
Cardboard pop-up single-dose dry powder inhaler for drug delivery
Website: https://www.1nhaler.com
Cover Block
PUBLIC
| Name | 1nhaler Ltd |
| Tagline | Cardboard pop-up single-dose dry powder inhaler for drug delivery |
| Headquarters | Edinburgh, Scotland |
| Founded | 2017 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed (total disclosed ~$4,400,000) |
Links
PUBLIC
- Website: https://www.1nhaler.com/home-1
- LinkedIn: https://www.linkedin.com/company/1nhaler
- X / Twitter: https://twitter.com/1nhaler
Executive Summary
PUBLIC
1nhaler Ltd is developing a single-dose dry powder inhaler made from flat, credit-card-sized cardboard that folds into a three-dimensional device, aiming to offer pharmaceutical partners a low-cost, low-carbon alternative to traditional plastic inhalers [Archangels, 2024]. The company, founded in Edinburgh in 2017 by Don Smith and Lisa McMyn, has raised approximately $4.4 million in seed funding across three rounds led by Archangels, with support from Scottish Enterprise and BBB Investments [UK Tech News, Nov 2023] [Finsmes, Nov 2025]. Its propellant-free platform uses a proprietary membrane dispersion technology designed to support a variety of dry-powder medicines, targeting inhaled therapies for conditions from asthma and COPD to epilepsy and Parkinson's [Archangels, 2024].
The founding team has been bolstered by key appointments from major pharmaceutical companies, including Chief Scientific Officer Helen Muirhead, who led development of GSK's Diskus and Ellipta inhalers, and Board Chair Jane Gaddum, a former AstraZeneca marketing executive [Archangels, 2024]. The business model is exclusively B2B, positioning 1nhaler as a drug-delivery device partner for pharma and biotech companies seeking to develop or reformulate drugs for inhalation. Capital raised is being deployed to advance the platform toward a first Marketing Authorisation Application targeted for late 2027, which involves manufacturing clinical material and designing commercial-scale processes [Scottish Enterprise].
Over the next 12-18 months, the primary milestones to watch are progress in regulatory studies and the securing of a first named pharmaceutical development partnership, which would serve as a critical validation signal for the platform's technical and commercial feasibility.
Data Accuracy: YELLOW -- Core company description and funding totals are corroborated by multiple investor releases; team backgrounds and product claims are primarily sourced from a single investor publication.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (total disclosed ~$4,400,000) |
Company Overview
PUBLIC
1nhaler Ltd was incorporated in Edinburgh, Scotland, on August 11, 2017, by co-founders Don Smith and Lisa McMyn [GOV.UK]. The company operates as a drug delivery device developer, maintaining its registered office and headquarters in Edinburgh [GOV.UK] [1nhaler]. The founding narrative centers on developing a low-cost, sustainable alternative to traditional plastic inhalers, with the core concept of a flat, credit-card-sized device that folds into a three-dimensional inhaler emerging from this period [Archangels, 2024].
Key corporate milestones have unfolded through a series of seed funding rounds led by the Scottish angel syndicate Archangels. An initial raise of £2 million (approximately $2.5 million) was secured in 2023 to advance device development [UK Tech News, Nov 2023]. This was followed by an additional £1.5 million in seed funding, announced in 2024, with continued participation from Scottish Enterprise and BBB Investments [Scottish Enterprise]. The capital has been earmarked to progress the platform technology toward a first Marketing Authorisation Application (MAA), targeted for late 2027 [Archangels, 2024].
A significant milestone in 2023 was the assembly of a leadership team with deep pharmaceutical industry credentials. The company appointed Helen Muirhead, formerly Head of the Respiratory Centre of Excellence at GSK with development responsibility for the Diskus and Ellipta inhalers, as Chief Scientific Officer [Archangels, 2024]. In 2024, Jane Gaddum, a former Vice President for global marketing emerging brands at AstraZeneca, joined as Board Chair and Non-Executive Director [Archangels, 2024]. These appointments signal a strategic build-out of regulatory and commercial expertise ahead of clinical trials.
Data Accuracy: GREEN -- Company incorporation and headquarters confirmed by GOV.UK and company website. Funding rounds and leadership appointments corroborated by multiple investor and news sources.
Product and Technology
MIXED The core proposition is a physical device, not software, built to be simpler and cheaper than the multi-dose plastic inhalers that dominate respiratory care. 1nhaler's platform is a single-dose dry powder inhaler made predominantly from cardboard that folds from a flat, credit-card-sized form into a 3D inhaler for single-dose delivery [Archangels, 2024]. The company describes it as a 'pop-up cardboard inhaler' that is 'simple to use, cheap to make and small enough to slip into a wallet' [Archangels, 2024].
The technology is designed to be propellant-free, using a proprietary 'membrane dispersion technology' to deliver a variety of medicines in dry-powder format [Archangels, 2024]. This positions it as a potential platform for pharmaceutical partners to reformulate existing drugs or develop new ones for inhalation. The company has cited a broad range of target therapeutic areas, including asthma, COPD, influenza, anaphylaxis, epilepsy, depression, and Parkinson's [Archangels, 2024].
Manufacturing partnerships signal execution progress, though they are not commercial customer deals. The company has engaged with Upperton Pharma Solutions for clinical trial material and Harro Höfliger for the design of commercial-scale manufacturing processes [Scottish Enterprise, 2024] [HARRO, 2022]. The stated near-term goal is to advance the platform towards a first Marketing Authorisation Application (MAA) targeted for late 2027 [Scottish Enterprise, 2024].
Data Accuracy: YELLOW -- Core product claims are consistent across investor releases, but detailed technical specifications and independent performance data are not publicly available.
Market Research
PUBLIC The push for sustainable, patient-centric drug delivery is reshaping the economics of inhaled therapies, a market historically dominated by complex, multi-dose plastic devices. 1nhaler's bet is that a low-cost, single-use platform can unlock new applications and improve access, a proposition that depends on the underlying market's size and its receptivity to change.
Quantifying the total addressable market for a novel dry powder inhaler platform is challenging, as the company's value is tied to the drugs it could deliver rather than the device itself. Public third-party sizing for the global dry powder inhaler market is not cited in available materials. As an analog, the broader respiratory drug delivery devices market was valued at $34.5 billion in 2021 and is projected to reach $52.7 billion by 2028, according to a Fortune Business Insights report [Fortune Business Insights]. This figure encompasses all device types, including nebulizers and metered-dose inhalers, and serves as a rough upper bound for the category 1nhaler aims to penetrate.
Demand drivers are well-documented in industry literature. The primary tailwind is the growing prevalence of chronic respiratory diseases like asthma and COPD, which require long-term, often daily, medication. A secondary, and perhaps more strategic, driver is the expansion of inhalation as a route of administration for systemic conditions, including central nervous system disorders like epilepsy and Parkinson's [Archangels, 2024]. This shift is fueled by the potential for faster onset of action and bypassing first-pass metabolism compared to oral drugs. Environmental pressure is another catalyst; the healthcare sector's focus on reducing plastic waste and carbon footprints creates a receptive environment for a cardboard-based, propellant-free alternative to traditional inhalers.
Adjacent and substitute markets provide context for the platform's potential. The most direct substitute is the existing ecosystem of multi-dose DPIs (like GSK's Ellipta) and pressurized metered-dose inhalers. These are entrenched, but their complexity and cost can be prohibitive for single-dose or emergency use cases, such as anaphylaxis or breakthrough seizures. Another adjacent market is the nasal drug delivery segment, served by companies like OptiNose for migraine, which demonstrates the commercial viability of specialized, device-enabled delivery for non-respiratory indications.
Regulatory forces are a defining macro factor. Achieving a Marketing Authorisation Application (MAA) is the stated milestone for late 2027 [Scottish Enterprise, 2024]. The pathway will require demonstrating not only device safety and performance but also compatibility with specific drug formulations. Success would grant the platform a significant regulatory moat, but the timeline and capital required are substantial risks. Furthermore, pricing and reimbursement pressures in global healthcare systems incentivize cost-reducing innovations, which aligns with 1nhaler's low-cost manufacturing thesis.
Respiratory Drug Delivery Devices Market (2021) | 34.5 | $B
Projected Market (2028) | 52.7 | $B
The projected growth of the broader respiratory delivery market, at a compound annual rate of approximately 6.2% (estimated), indicates a steady expansion of the underlying category. However, this chart reflects the entire device universe, not the specific niche for single-dose, sustainable DPIs that 1nhaler is targeting.
Data Accuracy: YELLOW -- Market sizing is based on an analogous third-party report for the broader category; specific DPI platform TAM is not publicly quantified by the company or its investors.
Competitive Landscape
MIXED 1nhaler enters a drug delivery device market defined by large, established players and a handful of specialized innovators, with its primary competition hinging on the trade-offs between multi-dose convenience and single-dose simplicity.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| 1nhaler Ltd | Single-dose, pop-up cardboard DPI platform for pharma partners | Seed, ~$4.4M total (2023-2025) | Low-cost, low-carbon, propellant-free, credit-card-sized flat form factor | [Archangels, 2024] |
| MannKind Corp | Commercial-stage developer of inhalable insulin and other drugs using its Technosphere dry-powder delivery platform | Public (NASDAQ: MNKD), $1.3B market cap (Apr 2025) | Proprietary formulation technology enabling rapid absorption of large molecules like insulin | [MannKind, 2025] |
| OptiNose | Commercial-stage developer of nasal delivery devices and therapeutics (e.g., Xhance) | Public (NASDAQ: OPTN), ~$200M market cap (Apr 2025) | Bi-directional nasal delivery technology designed to target deep nasal passages | [OptiNose, 2025] |
| Impel NeuroPharma | Commercial-stage developer of precision olfactory delivery (POD) devices for migraine and CNS disorders | Public (NASDAQ: IMPL), ~$50M market cap (Apr 2025) | Device designed to deliver drugs through the upper nasal cavity to the brain | [Impel NeuroPharma, 2025] |
The competitive map splits into three primary layers. The first consists of the dominant, diversified medical device and pharmaceutical giants that own the multi-dose inhaler market. Companies like GSK (with its Ellipta and Diskus devices) and AstraZeneca are not direct platform competitors to 1nhaler, but they represent the entrenched standard of care and the ultimate customer base. A partnership with one of these firms is 1nhaler's stated commercial goal, making them both potential partners and formidable gatekeepers. The second layer includes the public, platform-focused companies like MannKind, OptiNose, and Impel. These firms have validated their delivery technologies through FDA-approved products, but they are generally tied to specific drug formulations or therapeutic areas. Their primary competition with 1nhaler is for partnership dollars and development resources from pharmaceutical companies.
1nhaler's current defensible edge is architectural, rooted in its material choice and form factor. The use of cardboard and a flat, pop-up design targets two pain points for partners: cost of goods and environmental footprint. This is a tangible, patent-protected differentiator from the molded plastic and complex mechanisms of incumbent DPIs [Archangels, 2024]. The edge is reinforced by the team's deep regulatory and device development expertise, specifically Chief Scientific Officer Helen Muirhead's prior responsibility for GSK's blockbuster inhaler platforms [Archangels, 2024]. This credibility is a perishable advantage, however. It provides a head start in navigating the complex path to a Marketing Authorisation Application (MAA), but it does not guarantee commercial adoption. The edge erodes if a competitor develops a similarly low-cost platform or if pharma partners prioritize other drug delivery attributes over sustainability.
The company's most significant exposure is its narrow focus on the single-dose use case. This creates a clear market segment,treatments for acute conditions like anaphylaxis, influenza, or rescue medications,but it inherently cedes the chronic disease market, where multi-dose devices dominate for patient convenience and adherence. A competitor like MannKind, with a platform already approved for chronic daily use (insulin), could theoretically adapt its technology for single-dose applications, entering 1nhaler's niche from a position of greater regulatory validation and manufacturing scale. Furthermore, 1nhaler does not own a proprietary drug formulation, placing it in a potentially weaker negotiating position compared to a company that controls both the drug and the device.
The most plausible 18-month scenario involves 1nhaler securing its first formal development partnership with a mid-sized pharma or biotech company, likely for a niche acute therapy. Progress here would validate the platform's technical feasibility to partners. The winner in this period would be a company like Impel NeuroPharma if it successfully expands its POD platform into new central nervous system indications, demonstrating the value of specialized delivery to the brain and attracting further partnership deals. The loser would be any platform developer that fails to announce a new partnership or clinical milestone, as the market for drug delivery innovation continues to consolidate around a few validated technologies. For 1nhaler, the next phase is less about beating a specific named competitor and more about proving its cardboard platform can meet the exacting standards of pharmaceutical manufacturing and regulatory approval.
Data Accuracy: YELLOW -- Competitor profiles and funding are public, but 1nhaler's specific competitive advantages are based on company and investor claims.
Opportunity
PUBLIC The prize for 1nhaler, if its platform clears regulatory and commercial hurdles, is a position as a low-cost, sustainable standard for single-dose inhaled drug delivery across multiple therapeutic areas.
The headline opportunity is the establishment of a new device platform standard for pharmaceutical partners seeking to develop or reformulate drugs for inhalation. This outcome is reachable because the company is not merely selling a single device but a manufacturing-ready, propellant-free system designed to be integrated into drug development pipelines. The cited evidence points to a team that has successfully built and commercialized blockbuster inhaler platforms before, with Chief Scientific Officer Helen Muirhead having had development responsibility for GSK's Diskus and Ellipta devices [Archangels, 2024]. The company's stated target of a first Marketing Authorisation Application (MAA) by late 2027 provides a concrete, multi-year development roadmap that aligns with typical pharmaceutical partner timelines [Scottish Enterprise, 2024]. The opportunity lies in becoming the default, sustainable DPI partner for biotech and pharma companies, particularly for drugs requiring single-dose or short-course administration.
Multiple, distinct paths exist for the company to achieve scale. The following scenarios outline plausible routes to significant commercial traction.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Respiratory Anchor | The device becomes the preferred platform for next-generation rescue or short-course respiratory drugs (e.g., for asthma, COPD, influenza). | A development partnership with a mid-to-large pharma company to co-develop a specific drug-device combination. | The team's deep respiratory expertise from GSK and AstraZeneca provides credibility and network access in this core market [Archangels, 2024]. The platform's design targets these exact use cases. |
| CNS Breakthrough | The platform enables a novel, inhaled formulation for a central nervous system disorder (e.g., epilepsy, depression), creating a new category of rapid-acting treatments. | Successful completion of a Phase I/II clinical trial for a partnered CNS drug, demonstrating proof-of-concept for systemic delivery via the cardboard device. | The company explicitly lists epilepsy and depression as target therapeutic areas, indicating active exploration beyond respiratory [Archangels, 2024]. The single-dose, portable format is a potential differentiator for emergency or intermittent use in these conditions. |
| Sustainability Mandate | Environmental regulations or payer pressure on plastic waste in healthcare drive widespread adoption of the low-carbon device as a replacement for existing single-use plastic inhalers. | A major public healthcare system (e.g., NHS) issues a tender or guideline favoring sustainable medical devices. | The company's materials and environmental claims are a central part of its public narrative and investor messaging, positioning it ahead of potential regulatory shifts [Scottish Enterprise, 2024] [Daily Business, Nov 2025]. |
Compounding success for 1nhaler would look like a classic platform flywheel in medtech. An initial regulatory approval and partnership for one therapeutic area would generate clinical data, manufacturing scale, and regulatory precedent. This evidence package would de-risk the platform for subsequent pharmaceutical partners, reducing their development time and cost for new drug formulations. Each new partnership would further amortize the fixed costs of the device platform and manufacturing process, improving unit economics. The early engagement with contract development and manufacturing organizations (CDMOs) like Upperton and Harro Höfliger, as noted in the private take, signals the foundational work to establish this repeatable, scalable manufacturing process [HARRO, 2022]. The flywheel is predicated on the platform's reusability across drug molecules, turning one win into a template for the next.
Quantifying the size of a win requires looking at comparable companies that have successfully embedded their drug delivery platforms. While 1nhaler is pre-commercial, MannKind Corporation, a developer of dry-powder inhaler technology for insulin and other drugs, provides a relevant, if imperfect, public-market benchmark. As of early 2025, MannKind held a market capitalization of approximately $1.1 billion, derived largely from royalty streams on its Technosphere inhalation platform [Public financials, 2025]. A scenario where 1nhaler secures two or three meaningful pharmaceutical partnerships across different therapeutic areas could position it for a similar platform-royalty valuation model. If the Respiratory Anchor or CNS Breakthrough scenario plays out, the company's value would be anchored to the peak sales potential of the drugs using its device, typically commanding a mid-single-digit to low-double-digit percentage royalty. This represents a multi-hundred-million-dollar enterprise value opportunity (scenario, not a forecast).
Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from company and investor statements; market comparable is publicly available.
Sources
PUBLIC
[Archangels, 2024] 1nhaler appoints pharma industry leaders to board and secures funding to advance innovative inhaler platform | https://www.archangelsonline.com/news/1nhaler-appoints-pharma-industry-leaders-to-board-and-secures-funding-to-advance-innovative-inhaler-platform
[UK Tech News, Nov 2023] Scottish startup raises £2m for single-use inhaler | https://www.uktech.news/medtech/1nhaler-single-use-inhaler-20231127
[Finsmes, Nov 2025] 1nhaler Raises £1.5M in Funding | https://www.finsmes.com/2025/11/1nhaler-raises-1-5m-in-funding.html
[Scottish Enterprise] 1nhaler hires pharma industry leaders for key roles ahead of clinical trials | https://www.scottish-enterprise-mediacentre.com/news/1nhaler-hires-pharma-industry-leaders-for-key-roles-ahead-of-clinical-trials
[GOV.UK] 1NHALER LTD overview | https://find-and-update.company-information.service.gov.uk/company/SC573454
[1nhaler] About | https://www.1nhaler.com/home-1
[HARRO, 2022] 1nhaler - Passion and patience | https://www.harro-magazine.com/en/13-2022/1nhaler-passion-and-patience/
[Fortune Business Insights] Respiratory Drug Delivery Devices Market Size, Share & Industry Analysis | https://www.fortunebusinessinsights.com/respiratory-drug-delivery-devices-market-105175
[MannKind, 2025] MannKind Corporation Investor Relations | https://investor.mannkindcorp.com/
[OptiNose, 2025] OptiNose Investor Relations | https://investors.optinose.com/
[Impel NeuroPharma, 2025] Impel NeuroPharma Investor Relations | https://investors.impelnp.com/
[Public financials, 2025] Public market data for MannKind Corp | https://finance.yahoo.com/quote/MNKD/
[Daily Business, Nov 2025] Funding support for novel eco-friendly inhaler | https://dailybusinessgroup.co.uk/2025/11/funding-support-for-novel-eco-friendly-inhaler/
Articles about 1nhaler Ltd
- 1nhaler's Cardboard Pop-Up Targets a Single Dose for Asthma, Flu, and Epilepsy — The Edinburgh startup, backed by £3.5 million and a team of GSK and AstraZeneca veterans, aims to replace plastic inhalers with a flat, credit-card-sized device.